Evidence map›Paper›PMID 40257492›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Conjugation of hydrazine to PEGylated silica-coated magnetite nanoparticles as pH-responsive magnetic nanocarriers for covalent loading and controlled release of doxorubicin.

Seyed Masih Abtahi Naeini, Mehdi Faramarzi, Amir Heydarinasab

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Seyed Masih Abtahi NaeiniDepartment of Chemical Engineering, SR.C., Islamic Azad University, Tehran, Iran.
Mehdi FaramarziDepartment of Chemical Engineering, Gac.C, Islamic Azad University, Gachsaran, Iran. Mehdi.Faramarzi@iau.ac.ir.
Amir HeydarinasabDepartment of Chemical Engineering, SR.C., Islamic Azad University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a major health issue among women, and doxorubicin (DOX) is a commonly used treatment. However, its clinical application is limited by its considerable toxicity. This study introduces an acidity-responsive magnetite nanoparticle-based nanocarrier for effective breast cancer treatment. The magnetite nanoparticles were initially coated with [3-(2,3-epoxypropoxy)-propyl]-trimethoxysilane, an epoxysilane cross-linker, to enhance their stability and functional properties. Subsequently, NH

Indexed as

Antibiotics, AntineoplasticDoxorubicinDrug CarriersHydrazinesMagnetite NanoparticlesPolyethylene GlycolsSilicon DioxideCell SurvivalDelayed-Action PreparationsDrug LiberationFemaleHumansHydrogen-Ion ConcentrationMCF-7 CellsAntibiotics, AntineoplasticDelayed-Action PreparationsDoxorubicinDrug CarriershydrazineHydrazinesMagnetite NanoparticlesPolyethylene GlycolsSilicon DioxideDoxorubicinDrug deliveryHydrazineMagnetite nanoparticlesPEGylation

Identifiers

PMID40257492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.